Po16-472 High Level of Agreement Between the Ncep Atpiii and Idf Metabolic Syndrome Definition in the Chilean General Population: Results From the First National Health Survey 2003

Prevalence of metabolic syndrome using NCEP-ATPIII and ınternational dietetics federation (IDF) definitions: A cross- sectional study in Turkish adults

“…Although obesity and level of physical activity contribute significantly to the frequency of MetS, other factors, such as a genetic predisposition, may play a role (Abate, 2000;Thomas et al, 2000;Das, 2002). Similarly to our study, in previous studies, assessment of MetS using the IDF criteria identified a higher number of subjects than the NECP-ATPIII definition (DECODA, 2007;Deepa, 2007;Ucar et al, 2009;Lima et al, 2009;Valenzuela et al, 2007;Moebus et al, 2007). Another study conducted on Turkish adults (532 men and 1036 women) showed that age-and sex-adjusted prevalence of MetS was 38% by NECP-ATPIII and 42% by IDF, but similar to our study, the agreement between NCEP and IDF definitions was substantial (kappa: 0.77) (Day, 2007).…”

“…Our results have shown that, according to IDF criteria, the frequency of participants with high FBG and WC was higher than the frequency of participants fulfilling the ATP III criteria. Valenzuela et al (2007) analyzed data from a random subsample of 1,833 adults 17 years and older, based on the NCEP ATP III Update 2004 and the IDF 2005 criteria. The results of this study were that the prevalence of MetS components was 46, 30 and 52.6% for hypertension, high triglycerides and low HDL-C, respectively (common to both criteria).…”

El síndrome metabólico: De factor agravante a principal factor de riesgo patogénico en diversas enfermedades crónicas

“…En Chile, una muestra transversal evaluada en la Encuesta Nacional de Salud 2003, mostró una prevalencia de SMetab de 23% (aproximadamente 2,7 millones de chilenos), similar a la informada en países desarrollados 3 . Un re-análisis de esta encuesta con los criterios actualizados propuestos por NCEP ATP III e IDF 8 , indica que la prevalencia de SMetab en Chile se eleva a 32% y 37%, respectivamente, con un nivel de concordancia de 90% para ambos criterios, mucho mayor que la descrita en otros países 9 . Entre las enfermedades crónicas más prevalentes, la enfermedad cardiovascular (ECV) ateroesclerótica y la diabetes tipo 2 han sido identificadas como las consecuencias clínicas principales del SMetab 10 .…”